within Pharmacolibrary.Drugs.ATC.B;

model B01AD02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.009166666666666667,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.026,
    k12             = 330,
    k21             = 330
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AD02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Alteplase is a recombinant tissue plasminogen activator (rt-PA) used for thrombolytic therapy. It is mainly indicated for the treatment of acute ischemic stroke, myocardial infarction, and pulmonary embolism and is approved for use in many countries today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult healthy volunteers and patients, typically following intravenous bolus or infusion administration.</p><h4>References</h4><ol><li><p>Wang, L, et al., &amp; Xiong, Y (2024). Comprehensive Review of Tenecteplase for Thrombolysis in Acute Ischemic Stroke. <i>Journal of the American Heart Association</i> 13(9) e031692–None. DOI:<a href=&quot;https://doi.org/10.1161/JAHA.123.031692&quot;>10.1161/JAHA.123.031692</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38686848/&quot;>https://pubmed.ncbi.nlm.nih.gov/38686848</a></p></li><li><p>Glund, S, et al., &amp; Wolff, M (2023). Bioequivalence of Intravenous Alteplase from Two Different Manufacturing Processes in Healthy Male Volunteers: Results from a Two-Stage, Adaptive-Design Study. <i>Clinical pharmacokinetics</i> 62(7) 1023–1030. DOI:<a href=&quot;https://doi.org/10.1007/s40262-023-01253-3&quot;>10.1007/s40262-023-01253-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37248330/&quot;>https://pubmed.ncbi.nlm.nih.gov/37248330</a></p></li><li><p>Larrue, V (2005). Intravenous alteplase for acute ischaemic stroke. <i>Expert opinion on pharmacotherapy</i> 6(15) 2699–2709. DOI:<a href=&quot;https://doi.org/10.1517/14656566.6.15.2699&quot;>10.1517/14656566.6.15.2699</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16316308/&quot;>https://pubmed.ncbi.nlm.nih.gov/16316308</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AD02;
